ArticleJournal of endocrinological investigation2026
Changes overtime in primary and secondary empty sella: a comparative real-world study.
Article in Journal of endocrinological investigation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposePrimary (PES) and Secondary (SES) Empty Sella (ES) show similar radiological appearances, but they may be associated with variable degrees of pituitary dysfunction. Long-term comparative data are limited. This study aimed to compare baseline and longitudinal endocrine outcomes of PES and SES in a large single-center cohort.
methodsWe conducted a retrospective, longitudinal study including adults with ES followed at a tertiary endocrinology center between 2007 and 2025. ES was classified as PES or SES based on clinical history. Clinical and neuroradiological features, comorbidities, and pituitary hormonal assessments were collected at baseline and during follow-up.
resultsA total of 258 participants were included (64.3% women; median age 51.5 years; median follow-up 58.5 months). PES was more prevalent than SES (61.6% vs. 38.4%). At baseline, 41.1% of patients had at least one pituitary hormone deficiency, significantly more frequent in SES than PES (62.6% vs. 27.7%), with gonadotropic deficiency the most common alteration. During follow-up, pituitary function remained stable in most PES patients (83.3%), with a very low incidence of new deficiencies. In contrast, SES showed a significantly higher risk of developing new corticotropic, thyrotropic, and gonadotropic deficiencies. Arginine vasopressin deficiency occurred exclusively in SES.
conclusionIn this large longitudinal cohort, PES and SES showed distinct clinical and endocrine evolution. While PES was generally stable course over time, SES was associated with a higher risk of progressive pituitary dysfunction. These findings support systematic baseline endocrine evaluation in all ES patients and a tailored follow-up strategy, with closer surveillance for SES.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.